EyePoint Pharmaceuticals, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Financial statements are unaudited. The company develops sustained-delivery therapies for serious eye disorders, with EYP-1901 in Phase 2 trials and EYP-2301 in preclinical development.
Financial results and liquidity
- Q3 revenue: $15.2 million, up 52% from $10.0 million. License and collaboration revenue was $14.1 million, primarily from the Alimera YUTIQ transaction; product sales were $0.8 million versus $9.7 million.
- Q3 profitability: Operating loss was $14.4 million versus $18.4 million; net loss was $12.6 million, or $0.33 per share, compared with $18.4 million, or $0.49 per share. Higher R&D spending was partly offset by lower commercial expenses and higher interest income.
- Nine-month results: Revenue was $32.0 million, up 4%; operating loss was $58.7 million versus $55.9 million; net loss was $56.7 million versus $58.8 million. R&D expense rose 37% to $46.7 million, mainly due to EYP-1901 clinical trials.
- Cash and liquidity: Cash and cash equivalents were $133.0 million and marketable securities were $3.0 million at September 30, for $136.0 million combined. Total current assets were $150.2 million and current liabilities were $63.9 million.
- Cash flow: Operating cash flow was positive $25.0 million for the first nine months, versus an outflow of $52.4 million in 2022. The 2023 inflow was substantially supported by $57.4 million of deferred revenue and other working-capital changes, rather than operating profitability. Investing provided $43.8 million, including proceeds from securities sales; financing used $31.4 million.
- Debt and equity: The company repaid its $30.0 million remaining SVB term loan in May and terminated the facility; no debt remained at quarter-end. It recorded a $1.3 million extinguishment loss for the nine months. ATM sales of 902,769 shares generated approximately $9.6 million net proceeds.
- Margins: The filing reports operating expenses and losses but does not present a headline operating or gross margin measure.
Material changes versus prior periods
- YUTIQ rights were licensed to Alimera in May 2023, sharply reducing EyePoint’s direct product sales and commercial spending. Product sales fell 92% in Q3 and 55% for the nine-month period, while license revenue increased substantially.
- Alimera paid $75.0 million upfront; a further $7.5 million is payable in quarterly installments during 2024. EyePoint may receive low-to-mid double-digit royalties on qualifying U.S. sales from 2025 through 2028, above specified thresholds.
- Sales and marketing expense declined 92% in Q3 and 41% for the nine-month period, reflecting the YUTIQ rights transaction and discontinued DEXYCU promotion. R&D spending increased with clinical-trial activity.
- EyePoint recorded a $1.4 million restructuring charge for commercial workforce reductions related to the YUTIQ transaction. The company reported that implementation was expected to be substantially complete by year-end 2023.
Outlook, commentary and risks
- Management said $136.0 million of cash, equivalents and marketable securities was expected to fund the operating plan into 2025 under current assumptions about EYP-1901 trials and EYP-2301. The financial-statement liquidity discussion separately says resources are expected to fund current and planned operations for at least 12 months from issuance. Neither is a guarantee; the company expects continued losses and may need additional financing.
- Management reported positive interim masked safety data for EYP-1901, with no reported drug-related ocular or systemic serious adverse events among approximately 170 treated patients across the ongoing PAVIA and DAVIO 2 and completed DAVIO 1 trials, as of the disclosed follow-up periods. PAVIA and DAVIO 2 enrollment was complete; efficacy and later clinical outcomes remain uncertain.
- In August 2022, the company received a U.S. Department of Justice subpoena concerning sales, marketing and promotional practices, including DEXYCU. The company is cooperating and cannot predict the investigation’s duration, scope or outcome, or whether it will have a material impact.
- Alimera’s future royalty payments depend on its sales performance and specified thresholds. EyePoint also identifies clinical-development, manufacturing, financing, competition and intellectual-property risks. The planned Northbridge manufacturing facility has a 15-year, four-month initial lease term and estimated base rent of approximately $40.8 million; lease commencement was expected in the second half of 2024, and no lease asset or liability was recorded at quarter-end.
- The company reported that its Watertown facility inspection classification changed from Official Action Indicated to Voluntary Action Indicated in May 2023. It provided no formal financial or earnings guidance in this filing.
Most important facts for investors to verify
- Clinical-trial efficacy, safety, timing and costs for EYP-1901, plus the development plans and funding needs for EYP-2301.
- Whether Alimera makes the 2024 payments and achieves sales sufficient to generate potential royalties from 2025 onward.
- Underlying cash burn and runway excluding the one-time Alimera proceeds and deferred-revenue working-capital benefit; management’s runway estimate depends on trial and operating assumptions.
- The status and potential financial consequences of the DOJ investigation, and DEXYCU demand following the loss of pass-through reimbursement.
- Future capital needs, potential share dilution, and the costs and timing of the Northbridge facility.